Francisco Robert

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 553 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

Francisco Robert, Mark P. Ezekiel, Sharon A. Spencer et al. · Journal of Clinical Oncology · 2001 · 473 citations

Medicine, Oncology, Pharmacology +16

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.

James A. Bonner, Kevin P. Raisch, Hoa Q. Trummell et al. · PubMed · 2000 · 220 citations

Medicine, Oncology, Radiation Oncology +17

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

George R. Blumenschein, Rebecca Paulus, Walter J. Curran et al. · Journal of Clinical Oncology · 2011 · 164 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

Michael Fanucchi, Frank V. Fossella, Robert J. Belt et al. · Journal of Clinical Oncology · 2006 · 156 citations · Full text

Medicine, Oncology, Pharmacotherapy +16